Education
About Us
Working with TipRanks
Follow Us
Lipocine (LPCN)
NASDAQ:LPCN
Total Valuation
Lipocine has a market cap or net worth of $16.10M. The enterprise value is $4.46M.
Market Cap$16.10M
Enterprise Value$4.46M
Share Statistics
Lipocine has 5,350,356 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding5,350,356
Owned by Insiders15.89%
Owned by Institutions<0.01%
Financial Efficiency
Lipocine’s return on equity (ROE) is <0.01 and return on invested capital (ROIC) is -5.09%.
Return on Equity (ROE)<0.01
Return on Assets (ROA)<0.01
Return on Invested Capital (ROIC)-5.09%
Return on Capital Employed (ROCE)-0.06
Revenue Per Employee699.88K
Profits Per Employee522.00
Employee Count16
Asset Turnover0.50
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Lipocine is 3.12K. Lipocine’s PEG ratio is -31.18.
PE Ratio3.12K
PS Ratio1.69
PB Ratio1.24
Price to Fair Value1.24
Price to FCF-19.87
Price to Operating Cash Flow-21.33
PEG Ratio-31.18
Income Statement
In the last 12 months, Lipocine had revenue of 11.20M and earned 8.35K in profits. Earnings per share was 0.00.
Revenue11.20M
Gross Profit11.20M
Operating Income-1.16M
Pretax Income9.03K
Net Income8.35K
EBITDA-1.11M
Earnings Per Share (EPS)0.00
Cash Flow
In the last 12 months, operating cash flow was -1.22M and capital expenditures -90.09K, giving a free cash flow of -1.31M billion.
Operating Cash Flow-1.22M
Free Cash Flow-1.31M
Free Cash Flow per Share-0.25
Dividends & Yields
Lipocine pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.90
52-Week Price Change-30.11%
50-Day Moving Average3.27
200-Day Moving Average4.47
Relative Strength Index (RSI)50.25
Average Volume (3m)11.88K
Important Dates
Lipocine upcoming earnings date is May 8, 2025, TBA Not Confirmed.
Last Earnings DateMar 13, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend Date―
Financial Position
Lipocine as a current ratio of 14.75, with Debt / Equity ratio of 0.00%
Current Ratio14.75
Quick Ratio14.75
Debt to Market Cap0.00
Net Debt to EBITDA5.57
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Lipocine has paid 681.00 in taxes.
Income Tax681.00
Effective Tax Rate0.08
Enterprise Valuation
Lipocine EV to EBITDA ratio is -17.82, with an EV/FCF ratio of -15.14.
EV to Sales1.77
EV to EBITDA-17.82
EV to Free Cash Flow-15.14
EV to Operating Cash Flow-16.25
Balance Sheet
Lipocine has $21.63M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$21.63M billion.
Cash & Marketable Securities$21.63M
Total Debt$0.00
Net Cash-$21.63M
Net Cash Per Share-$4.04
Tangible Book Value Per Share$3.93
Margins
Gross margin is 83.26%, with operating margin of -10.31%, and net profit margin of 0.07%.
Gross Margin83.26%
Operating Margin-10.31%
Pretax Margin0.08%
Net Profit Margin0.07%
EBITDA Margin-9.95%
EBIT Margin-10.31%
Analyst Forecast
The average price target for Lipocine is $6.75, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$6.75
Price Target Upside112.26% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast10081.34%
EPS Growth Forecast―